Posts

7 days in healthcare (March 18th-24th, 2024)

 

Summary

From the point of view of Biomedicine, the transplant to a man of a genetically modified pig kidney stands out, a medical milestone that could lead to dialysis being declared obsolete, which would be an extraordinary advance and an improvement in the quality of life for hundreds of thousands of patients, currently dependent on the machine several times a week for their survival. Also notable is the beginning of a clinical trial on a vaccine for tuberculosis. The current BCG vaccine offers protection to infants and young children, but does not protect adults and adolescents from pulmonary tuberculosis. If the results are good, this vaccine can be transformative.

As far as Global Health is concerned, a study warns of serious declines in birth rates globally, which will mean that by 2050 it will fall below population replacement, which will have important social and labor changes.

Regarding International Health Policy, a great paradox in the USA, although abortion is prohibited in 14 states and restricted in many others, in 2023 there were more abortions than ever, many of them non-instrumental and through the abortion pill, already responsible of 60% of abortions. China is facing a population decline, a phenomenon that has already begun. The one-child policy, in force for 36 years, is only one of the causes of this phenomenon. The European Union is advancing in the approval of pharmaceutical legislation, contemplated with reluctance by both the EFPIA and Medicines for Europe (the two large European pharmaceutical associations). The Lancet sees the upcoming European elections as an opportunity to put health policy higher on the EU agenda.

If we talk about National Health Policy (Spain), three important initiatives of the Ministry of Health: anti-smoking plan, modification of the medical guard regime and waiting lists. In all three cases there may be problems due to the powers and regulations of the autonomous communities. From the point of view of the regions, the OPE of Asturias stands out, which brings together 19,000 candidates. Although logically, temporality was and is a serious problem of public healthcare, which needed a solution, the way to do it through macro-OPE’s (consolidating the position in property, and with hegemony of the administrative and union logic, above the professional and autonomy of organizations) does not seem to be the best. This type of mass examination is more reminiscent of previous calls for the “military service”, when it was in force, than the professional selection for complex organizations, in which the professional qualification, the needs of the different organizations, the projects of the services, etc. should be taken into account.

As for Companies, on an international level, China is seen as the large market for anti-obesity drugs. Bayer wants to renew its portfolio, entering into cell and genetic therapies. As for Spain, the CNMV has released its report on Grifols, with several objections to its accounts. Faes Farma is preparing to grow in Latin America. For its part, DKV, the health insurer, wants to concentrate on group insurance.

Biomedicine

Global Health

International health policy

National health policy

Companies

7 days in healthcare (February 26th-Mars 3rd, 2024)

 

Summary

From the point of view of Biomedicine, certain advances stand out in the search for a treatment for multiple sclerosis, a disease that affects 1.8 million globally and for which at this time there is no effective therapy. As announced by the president of the Spanish Society of Nephrology, the new drugs will allow many cases of dialysis and transplant to be avoided.

As far as Global Health is concerned, the most worrying thing is the poor perspectives observed regarding the pandemic treaty, the objective that the WHO had proposed for 2024. The obstacles are the accumulation of vaccines and the sharing of knowledge about them, problems of rich countries and companies, respectively. The Lancet warns about the need to strengthen cervical cancer screening, which continues to cause hundreds of thousands of deaths a year, especially in low- and middle-income countries. Warning about ultra-processed foods (cereals, protein bars, soft drinks, and fast food) linked to 32 harmful health effects, including increased risk of vascular disease, cancer, type 2 diabetes, mental illness and premature death.

In terms of International Health Policy, a very serious problem with fentanyl in the United States, which in the last twelve months until September 23 had caused 105,000 deaths in that country. Until now, the policy was aimed primarily at preventing the entry of drugs; some extremist politicians had even proposed invading Mexico to put an end to the gangs. With the current Administration, efforts are directed more towards discouraging its use and treating addicts. Big problem for Republicans in the USA with the decision of the Alabama Supreme Court to declare frozen embryos as “extra-uterine children”, with all the obstacle that this has for the popular procedure of in vitro fertilization, so widespread in the United States as in other developed countries. This Alabama decision seems like a gift to Democrats: “First it was abortion, now it is in vitro fertilization and then it will be birth control,” warned Hillary Clinton. Even Trump was forced to distance himself from this decision. In France, the National Assembly is putting pressure on the pharmaceutical industry regarding the shortage of medicines, forcing laboratories to have a four-month reserve of “medicines of high therapeutic interest.” In order to strengthen drug R&D, the European Union is considering “giving away” a year’s patent to those drugs whose research has been carried out in Europe.

If we talk about National Health Policy (Spain), the current Ministry of Health, unlike previous Ministries, wants to get involved in the problems of the SNS, while the previous ones wanted to get involved as little as possible, with the argument that “everything was transferred” . This attitude seems, in principle, positive for the SNS. Another thing is priorities. It seems that among these are the suppression of 24-hour medical guards; addressing waiting lists; and, the State Public Health Agency. Regarding the first issue, the challenge is formidable, since medical guards, regardless of whether they are necessary or not, have become an important salary supplement. It is impossible to address this issue without considering the complements of medical personnel, which is no small issue. Regarding waiting lists, aware that their management corresponds to the communities, it seems that they want to establish a kind of “best practices”, with economic incentives for the communities that apply them. Not an easy matter either. And as for the State Public Health Agency, the ministry seems to have reached an agreement with the PNV and Junts, for the withdrawal of their amendments to the law. Let us hope that this agreement does not go against the strength and operation of the new Agency. For its part, SESPAS, the Spanish Society of Public Health, has published an interesting document on the characteristics that this body should have, with 11 very interesting recommendations. The Economic and Social Council of Spain (CES) publishes a report on the health system. Although the report is well prepared, it is difficult to find anything new in it that has not already been said or any innovative proposal. Taking advantage of the day of rare diseases (although it is now preferred to call them minority) the Spanish Association of Orphan and Ultra-orphan Drug Laboratories releases a report on the situation of these drugs in Spain. Much has been improved, although there is still room to advance. Both the La Paz hospital in Madrid and the Sant Joan de Deu in Barcelona launch special units to treat this type of illness.

As for Companies, on an international level, the Danish Zealand Pharma, a new relevant player in the field of obesity. On the national level, Viamed will launch a comprehensive unit for women in its hospital in Tarragona. New punishment in the Grifols Stock Market.

Biomedicine

Global Health

International health policy

National health policy

  • 24 hour guards
    • The Ministry of Health wants to end 24-hour medical guards this term. The Ministry will study the legislative framework that the autonomous communities can apply. The aim is to organize it by hospitals and without losing salary, since the guards can represent up to a quarter of the professionals’ salary. The challenge is formidable, since it must be implemented by the autonomous communities, it involves a reorganization of hundreds of services, an increase in staff and addressing the complements of medical personnel (https://www.eldiario.es/sociedad/sanidad-quiere-finish-medical-guards-24-hours-we-will-give-you-answer-legislature_1_10957897.html)
  • Economic and Social Council (CES) report on the health system
    • Report from the CES on the health system. Among the recommendations it supports public health and prevention; specify and update the SNS service portfolio; make Primary Care the true axis of the system; confront waiting lists; strengthen the comprehensive mental health model; enhance the quality of pharmaceutical provision; promote the planning and reinforcement of human resources of the SNS; reinforce patient participation; contribution of the private for-profit and non-profit sector; improvement of system management and evaluation (https://www.ces.es/documents/10180/5299170/INF_012024.pdf)

Companies

 

 

7 days in healthcare (February 12th-18th, 2024)

Summary

From the point of view of Biomedicine, as is known, most rare diseases have no treatment, although this situation will surely be overcome in the not too distant future. A new drug (prozelimab) against the rare Chaple disease. A trial offers hope that a jab could prevent rheumatoid arthritis, the disease that affects 18 million people globally. Chances of a blood protein test warning about the onset of Alzheimer’s disease up to fifteen years in advance. A new powerful antibiotic (cresomycin), hope for antimicrobial resistance, which globally causes about five million deaths a year.

Regarding Global Health, despite the fact that 2021 marked the 100th anniversary of the appearance of insulin, many diabetes patients still do not have access to it. Important article in the New England Journal Medicine about e-cigarettes. There is sufficient evidence to show that switching from cigarettes to e-cigarettes reduces exposure to tobacco toxins, decreases respiratory symptoms, and reverses physiological changes related to cigarette smoking. There is not enough evidence that e-cigarettes are a good method to quit smoking.

In terms of International Health Policy, an unexpected consequence of the ruling of the United States Supreme Court, granting states the possibility of legislating on abortion, what was widely used to prohibit or restrict it: the taking of prescribed abortion pills by telemedicine and received by mail is a safe and effective method, according to a study. The European Commission approves the first gene editing treatment, in this case for beta thalassemia and sickle cell anemia. HERA (Health Emergency Preparedness and Response Authority) launches the Critical Medicines Alliance. It is said that this Alliance will contribute to changing the way medicines are produced and purchased in Europe.

If we talk about National Health Policy (Spain), there is great commotion in the sector as a result of the statements by Vice President Yolanda Díaz that she is negotiating to introduce in the budgets the modification of the health VAT from 0% to 21%. Regardless of the viability of this proposal, could it be considered whether this is the best way to make policy? Any study on the impact on the sector? Any previous negotiations with the health ecosystem? Although the Ministry of Health usually intervenes little in economic matters – remember that all the cuts during the financial crisis were not even discussed in the Interterritorial Council of the National Health System – this is a major issue that well deserves a position. and an analysis by the Ministry of Health. Asturias regulates financial compensation to professionals (442 euros for four hours of surgical activity and half for consultations for doctors) for extension of working hours to address the serious problem of waiting lists. Family doctors report a deficit of 2,600 professionals in the next year. As a consequence of the European Plan against Cancer, the launch of the first nine Comprehensive Cancer Centers in Spain is announced. The project is led in Spain by the Vall d’Hebron Hospital and the National Institute of Oncology.

As for Companies, on an international level, the British consulting firm Clarivate analyzes the 13 disruptive drugs for 2024. Oncology drugs predominate, although there is also the vaccine against respiratory syncytial virus and a new drug against COPD. At the national level, the growth of the egg freezing business in Spain is confirmed. It seems that the HIPRA vaccine is going to end up in the trash. There is nothing special, since failures are inherent to business, especially in an area as difficult as biotechnology. However, some excessively triumphalist government demonstrations could have been avoided.

Biomedicine

Global Health

International health policy

  • United Kingdom and the National Health Service

National health policy

Companies

7 days in healthcare (January 1st-7th, 2024)

 

Summary

From the point of view of Biomedicine, scientists celebrate a new antibiotic, currently undergoing Phase 1 clinical trials, that can kill resistant bacteria. The magazine Nature publishes precisely an editorial in relation to the need to encourage the appearance of new antibiotics against resistant bacteria. The problem is that the current business model in the pharmaceutical industry does not introduce incentives to companies for investments in this field. This is why it proposes “push” solutions (strategies to reduce the cost that may include government aid for the initial stages of research) and “pull” (compensating companies that develop successful antibiotics).

As far as Global Health is concerned, we should mention an interesting article in The New York Times about the need to set up a kind of global immune system against multiple health threats. It would consist of a system of detection and immediate action. Great progress towards the objectives in relation to HIV, almost reaching the aspiration of achieving 95-95-95 (95% of patients with HIV, diagnosed; 95% with antiretroviral treatment; and, 95% with viral suppression).

In terms of International Health Policy, Case and Deaton’s theory in the United States of deaths due to despair (alcohol, drugs and suicide) seems to be dismantled, which would affect mainly white American men without university studies and who had reached relate even to Trump’s victory. Recent studies show that these deaths are not limited to this population, but affect all social classes. Also in the United States, the authorization by the FDA of the importation of medicines from Canada by the State of Florida is of great significance. The price is substantially cheaper for these medications than the one currently in force in the USA. Pharmaceutical companies have cried foul, since this is the first time this has happened in the USA. Litigation is more than assured. The tripledemic (respiratory infections of influenza A, covid and RSV in children) is spreading throughout Europe, with Spain and Italy being precisely the most affected countries.

If we talk about National Health Policy (Spain), the Interterritorial Council of the SNS will address next Monday (January 8) the measures against the tripledemic, in particular the possible mandatory nature of masks in health centers, something already imposed by some communities . The overcrowding in hospital emergencies highlights the absence of demand management: more role for Primary Care; less face-to-face activity  and online attention; and more paper for nursing. The El Español Health Observatory makes public a document of proposals for the health system, the result of the symposium held between October 2-5, 2023, with the participation of more than 150 speakers. The common genetics portfolio of the SNS will be presented on January 23, in what appears to be a great advance for the system. The Ministry of Health of Andalusia announces measures against waiting lists, based on what they call “restructuring the bases of activity.” Without a specific budget, trying to act on productivity without adequate management tools and avoiding agreements with the private sector, we dare say that the measures are doomed to failure.

In the field of Companies, on an international level, what stands out as a novelty is that Lilly is entering B2C, launching in the United States a website for direct sales of medicines to the public and even with a direct home delivery service. A very innovative experience, of which we will have to see the results. As far as Spain is concerned, Domus Vi sells five residences.

Biomedicine

Global Health

International health policy

  • USA
    • The theory of “deaths of despair” (Case and Deaton) no longer holds. This theory, which caused a lot of impact, said that in the USA deaths due to despair (alcohol, drugs and suicide) mainly affected whites without university education. This has changed and today it is known that they affect practically all social classes, without special predominance of the groups indicated by Case and Deaton (https://www.economist.com/united-states/2023/12/23/the-deaths-of-despair-narrative-is-out-of-date)
    • The FDA approves the first mass importation of medicines from Canada to Florida. The price is much lower than that of medicines in the USA, pharmaceutical companies are opposed and it is believed that the PhRMA (representative of American pharmaceutical companies) will file an appeal. Florida says it will save $150 million with the program in the first year alone. It is the first time that something like this has happened in the USA (https://www.nytimes.com/2024/01/05/health/drug-imports-canada-florida.html)
    • The rise in rates and costs drives the bankruptcy of healthcare companies. 18 healthcare companies went bankrupt in the last year. (https://www.ft.com/content/65dfbc81-2641-48fa-a40a-647076943194)
  • Europe
    • Europe fights against the tripledemic of respiratory infections. Tripledemic is the coexistence of covid, influenza A and RSV in children. Spain and Italy, the most affected countries. Also Germany and France. The term means that all three infections coexist, not that individuals have more than one disease. In fact, there are few cases of co-infection (https://www.ft.com/content/449c4748-ef63-4f0a-b26e-4e528889fac4)

National health policy

  • Recruitment of doctors in the Basque Country
    • After requiring Basque from doctors, it is now proposed to hire foreigners without requiring it (https://www.eldebate.com/sociedad/20240105/pais-vasco-queda-medicos-imponerles-euskera-ahora-contratara-extranjeros-exigirselo_164608. html – :~:text=The Government of the Basque Country, first time to non-EU personnel.)

Companies

 

 

7 days in healthcare (December 4th-10th, 2023)

 

Summary

From the point of view of Biomedicine, Nature magazine analyzes the clinical trials that will shape medicine in 2024, including genetic editing for hypercholesterolemia; AI for early diagnosis of lung cancer; HIV vaccines; stem cells for Parkinson’s; the use of machine learning for patient triage; conjugated antibodies for brain metastases; and, computed tomography for lung cancer screening. The New England Journal of Medicine analyzes whether clinical trials with xenotransplants should be “liberalized” in the absence of human donors, especially in the United States.

Regarding Global Health, at COP28, 124 countries, including Spain, sign a Declaration on Climate and Health. It remains surprising, however, that the president of the COP28 meeting, held in Dubai, is the president of that country’s state oil company, which did not stop expressing its skepticism regarding decarbonization actions. On the other hand, populist leaders around the world (Wilders, Milei, Bolsonaro, Trump) have made climate change denial an electoral platform. Decline of AIDS worldwide, particularly in sub-Saharan Africa.

In terms of International Health Policy, the White House creates an Office for the Prevention of Firearm Violence. Large drop in state health insurance policyholders in China, the largest health insurance organization in the world. In the United Kingdom, the Tony Blair Institute for Global Change analyzes the high and increasing cost of being overweight. Many Britons, despite their adoration of the NHS, choose to pay for certain interventions and procedures, in order to avoid the waiting list. In that country, this form of payment for certain actions is more common than insurance, which is expensive in Britain. Germany announces a plan to strengthen the pharmaceutical industry. It seems that the promotion of research and production in the country will be the main axes. The European Union definitively approves the AI law, the first law in the world on this subject. Without a doubt, it will have a great impact on health.

If we talk about National Health Policy (Spain), after the constitution of the writing team appointed by the Ministry of Health in October 2021, 2023 is about to end without the official report on the management of the pandemic having been made public, which which puts us behind many countries that have already published analyzes and reports. On the other hand, it does not seem that, contrary to what was done in other countries, such as the United Kingdom, where even Boris Johnson had to appear, the Spanish commission has sought the opinion of many actors. Surely the delay in publication could come from the problems of managing the pandemic in our country: two confinements declared unconstitutional by the Constitutional Court, delay in decision-making, high mortality figures at the beginning, high mortality among professionals, serious problems in purchasing supplies, etc. The Minister of Health takes her first steps, having to face in the coming weeks the problem of the lack of doctors in Primary Care. In Asturias, the autonomous community will dedicate 57 million extra hours for professionals to address the problem of waiting lists. A measure that seems reasonable and that overcomes the criticism of the so-called “peonadas”, as if activity in the public sector could not be controlled.

In the field of Companies, on an international level, Roche is jumping on the obesity bandwagon, following moves in this direction by NovoNordisk, Lilly and AstraZeneca. In our country, Ribera is finalizing the purchase of IMSKEN, an important trauma hospital in Valencia. The bankruptcy administrator and creditors are demanding the seizure of KKR, which they accuse of the bankruptcy of Dentix.

Biomedicine

Global Health

International health policy

  • China
    • The Chinese state health insurance, the largest in the world with 1.3 billion insured, loses tens of millions of members. In 2022, 19 million people were no longer covered, an unprecedented drop. It is blamed on the rise in premiums and co-payment increases and the decline in household income, https://www.ft.com/content/0ef68e30-bbe7-4b6e-8d17-479a552be994

National health policy

  • Lack of professionals in Primary Care

Companies

7 days in healthcare (October 23rd-29th, 2023)

 

Summary

From the point of view of Biomedicine, Nature magazine analyzes the great impact of Artificial Intelligence in medicine. Interesting article from the New York Times about the possible addictive nature of social networks.

Regarding Global Health, the WHO adds 6.9 million deaths from covid, although warning that the global figure could triple. Major humanitarian and health crisis in Gaza, which is the subject of WHO concern.

In terms of International Health Policy, the NEJM wonders if the introduction of the American government’s law that requires negotiating the price of drugs for Medicare will delay the appearance of new cancer drugs. The conclusion is that, although pharmaceutical companies will look for ways to maintain their profits, delaying the appearance of medications does not seem to be the best strategy, due to the ethical, reputational and financial considerations inherent to the operation. The Economist analyzes how it seems that healthcare has ceased to be the bottomless pit for public accounts, as it was for many years, in which, year after year, its relative weight in the countries’ GDP increased. Although health expenditure increased its share of GDP in the years 20-21, due to the joint effect of health expenditure due to the pandemic and the decline in GDP, it has since fallen to reach 2008 levels. In the United Kingdom, It seems highly unlikely that Prime Minister Sunak will deliver on his promises on NHS waiting lists.

If we talk about National Health Policy (Spain), given the evolution of the negotiations for the investiture and the possible continuity of Sánchez in the government, the national news of the week is the publication of the document “Spain advances”, which contains the agreements of the PSOE with SUMAR on different topics. The general tone of the document is more about promises than progress in certain necessary reforms and this same philosophy permeates the health part. On the other hand, the document does not cover all the topics (it does not talk about Defense, very little about foreign policy or other relevant issues). It gives the impression that this is the part in which SUMAR would intervene. From this point of view, as the health part is developed in some detail, it is assumed that a strong intervention by SUMAR in health is expected, regardless of whether the Ministry of Health is handed over to it. In summary, what is promised is to continue the processing of the Equity Law (which establishes direct public management as the preferred form of management in the SNS), a law is proposed with maximum times for waiting lists and there is talk of new benefits in mental health, oral health (although it seems to limit it to children and adolescents) and visual health. We consider the emphasis on the preferential nature of direct public management negative (there is multiple evidence of the good results of public companies and foundations or health concessions) and regarding the law on the waiting list it will surely not be the best way to solve this problem. We have already seen laws and regulations in some communities that had no effect. Both the PP, in the political sphere, and ASPE and ACES, in the world of health representation, have been against these measures.

In the field of Companies, on an international level, Amazon is torn between promises and realities in healthcare. Although large technology platforms will surely have an increasing role in healthcare (as in the financial world), it seems that they are finding it difficult to enter. Roche reaches an agreement to buy Telavant. At the national level, Ribera reaches an agreement with Microsoft to promote innovation and AI in healthcare. It seems that Grifols is making progress in its therapy against Alzheimer’s.

Biomedicine

Global Health

International health policy

National health policy

Companies

7 days in healthcare (August 21st-27th, 2023)

 

Summary

From the point of view of Biomedicine, to highlight the results of the devices that read the brain and allow certain people to speak using their thoughts. In September the Human Brain Project will be presented, the most ambitious research project financed by the European Union. The British NICE recommends stool tests to be carried out at home for colorectal cancer screening.

As regards Global Health, the journal Science analyzes how climate change can amplify epidemics and give rise to new pandemics.

Regarding International Health Policy, important developments in the USA: the CDC establishes new standards for the approach to sepsis in hospitals; large increase in sex change surgeries in recent years; AstraZeneca is suing the American government for its plans to negotiate the price of medicines, which reflects the great tension between the pharmaceutical industry and the American government, which next week will reveal the 10 medicines on which the price is going to be negotiated; and, a large increase in mental health spending after the pandemic, something that is not expected to change. The British Nuffield Trust analyze the income of English doctors in the various categories. The WHO launches an interesting digital health initiative.

If we talk about National Health Policy (Spain), the Ministry of Public Health publish in the BOE the call for specialized health training with places for doctors, pharmacists, nurses, psychologists, chemists, biologists and physicists. The Ministry also publishes a very complete analysis on the relevance of lung cancer screening. Although it has been said that the Ministry refuses to implement this screening, the truth is that it has limited itself to publishing the report, which will be analyzed by the Interterritorial Council. In Europe there is no public system that has programs of this type in place. The positions of the Scientific Societies must be heard, but they are not the only ones to consider, taking into account that these Societies usually support everything that favors the activity of the respective specialty. But in these types of decisions, many circumstances must be weighed, including cost/effectiveness. Important confrontation between doctors and health insurers in Seville, which will take place throughout September. Some complaints from physicians have been made public in relation to the SELENE computer program, which is widely implemented in the hospital public sector. A subject on which it is difficult to pronounce, but clearly to follow, due to its importance. Having a user-friendly, fast computer application with innovative features is essential for medical practice.

In the field of Companies, internationally, it seems that Roche and MSD will lead the billing of pharmaceutical companies in the next five years. As far as national news is concerned, Europe is not opposed for competition reasons to the agreement between Esteve and Lubea.

Biomedicine

Global Health

International Health Policy

National health policy

Companies

 

 

 

7 days in healthcare (June 26th-July 2nd, 2023)

 

Summary

From the point of view of Biomedicine, clinical trials in humans begin with drugs developed by artificial intelligence, such as one for idiopathic pulmonary fibrosis. Álvaro Pascual-Leone, a prestigious Spanish neuroscientist based in the United States, announces that in about ten years the brain will be able to be manipulated . Surely at that time the manipulation of the brain will be something as normal as today the replacement of the crystalline lens for the cataract. A new world is coming.

In Global Health, two charities (the Gates Foundation and the Wellcome Foundation) set to fund a TB vaccine, which could save 8.5 million lives over the next quarter century. Gavi, the organization that provides vaccines to developing countries, approves a vaccine that protects against polio and five other diseases.

Regarding International Health Policy, the editor of the American Journal Medicine publishes in the last issue an article with the five great challenges of the American health system in the 21st century. However, from a reporting point of view, the most interesting news comes from the UK. The King’s Fund, a major British health think tank, publishes a comparative analysis of that country’s health system, which it analyzes together with 19 health systems, including the Spanish one. The analysis is very interesting, and the conclusion is that the NHS is efficient, but with big problems, not only with waiting lists, but also with results. It seems to imply a chronic underfunding of the NHS, when compared to systems in other countries. For its part, the NHS publishes for the first time a long-term plan on personnel. It basically deals with three things: training, retention and reform. The Guardian hails the report but says it is years overdue. For their part, both The Lancet and the British Medical Journal publish editorials on the 75th anniversary of the NHS, which coincides with its deep crisis. In both positions, political consensus is claimed as a key piece to fix the serious problems of the NHS. The WHO-Europe publishes a document with architectural recommendations on the hospitals of the future.

If we talk about National Health Policy (Spain), there are several news of interest: the Audit Office of Catalonia publishes an interesting report on waiting lists. It seems that 9% of the cases on the waiting list in Catalonia were not counted on the Department of Health website, which leads some to use the word makeup. With regard to private healthcare, the IDIS is starting a very interesting project to share the patient’s clinical history among various provider and insurer entities, only an initial but very important step in what is to come. In the course of the pre-election debate, the President of the Popular Party announces a new General Health Law and a State Pact on Health if it reaches La Moncloa. Interesting announcements since, as The Lancet says for the NHS, only a certain political consensus and a new partnership, will be able to solve the problems of the health system in our country.

At the Corporate level, internationally, GSK completes the acquisition of Bellus Health. As far as national news is concerned, we must highlight Roche’s investment in Sant Cugat.

Biomedicine

Global Health

International Health Policy

  • USA
    • The challenges of the American healthcare system in the 21st century, according to the editor of the American Journal Medicine. Five big challenges: 1. Insufficient insurance coverage; 2. Low health education among the population; 3. Prevention and management of chronic diseases; 4. Great disparities in quality and results; and. 5. Trust in doctors? (https://www.amjmed.com/article/S0002-9343(23)00035-9/fulltext)

National Health Policy

Companies

 

 

 

 

 

7 days in healthcare (May 1st-7th, 2023)

 

Summary

From the point of view of Biomedicine, to point out the interest in certain therapies using viruses that engulf bacteria to address infections caused by antibiotic-resistant bacteria. Progress continues to be made in breaking the blood-brain barrier, which will make it possible to better treat certain brain tumors, which until now have not been reached by medication.

As regards Global Health, the WHO declares the end of the emergency due to the covid pandemic, although not the covid, which is still with us. Since its inception this disease has caused more than 20 million deaths globally. Gavi reveals his plans for a malaria vaccine, another major global plague.

As for International Health Policy, he has highlighted the rise in the price of tobacco in France (a good measure against smoking), and Australia wants to limit the use of electronic cigarettes. The ECDC brings out an interesting report with the lessons of the pandemic: “More investment, improvement of surveillance systems, improvement of risk communication, community participation and greater participation between countries” could be the summary.

If we talk about National Health Policy (Spain), in the update of the Stability Program 2023-2026, the % of GDP dedicated to public healthcare spending does not change, remaining at 6.9%. It is evident that only increasing spending does not solve the problems of our health system, but it is difficult to see how they can be solved without increasing spending, as the government proposes. The Spanish Association against Cancer, through the mouth of its president, denounces that Spain has the cheapest tobacco in Europe: “the tobacconist of Europe” calls for this situation. Interesting article by Juan Abarca Cidón, who presents a decalogue to avoid the collapse of our health system. The measurements are very clear and direct. It will be possible to qualify or even disagree with some, but there is no doubt that the problems are addressed. Not like the framework programs of the majority parties for the 28-M elections, which seem to try not to raise any suspicion, by saying nothing.

At the Corporate level, at the international level, Lilly presents a new drug that slows down the progression of Alzheimer’s. The birth of a large market linked to Artificial Intelligence in health is in sight, according to the report by Siemens Financial Services. As far as our country is concerned, Cofares reaches a sales record in 2022. Grifols enters the field of leukemia.

Biomedicine

Global Health

International Health Policy

National health policy

  • Interesting article with a decalogue of reforms in our health system
    • Article by Juan Abarca Cidón, the proposals range from a political agreement; increase general spending on health; finalist financing with certain objectives; reduce costs, considering the co-payment; new governance model at all levels; new care organization model with a greater role for nursing; deal with patient problems, such as waiting lists; address the problems of professionals; normalize the activity of the private sector; and promote the Public Health Agency (https://www.elespanol.com/edicion/20230430/decalogo-reformas-evitar-colapso-sanidad/760293970_12.html)

Companies

 

 

7 days in healthcare (April 10th-16th, 2023)

 

Summary

From the point of view of Biomedicine, this week marked the 20th anniversary of the completion (later it turned out not completely) of the Human Genome Project, whose results were presented on April 14, 2003. A project that revolutionized biology and Medicine. Many of the treatments that are now in sight, such as gene editing, or the screening of certain diseases come from the progress of that project.

As far as Global Health is concerned, the criminalization of suicide (considering suicide attempts as a crime subject to fines or imprisonment) is still in force in more than 20 countries. Not so many years ago suicide attempts were decriminalized in advanced societies, as recently as 1966 in England or 1993 in Ireland. Clearly, what these suicidal individuals need is care and treatment.

As for International Health Policy, the United States continues to have problems with the Supreme Court’s decision to annul the FDA’s authorization of an abortion pill, a measure that was later put on hold. The crisis in the British NHS continues, with two important strikes called: nurses and junior doctors.

If we talk about National Health Policy (Spain), the incidence of covid has grown slightly in the last week. Medical and health conflicts continue in various autonomous communities: the Valencian Community, Galicia, the Canary Islands, Madrid and Andalusia. Great news, if confirmed, the arrival of the first publicly funded biomarkers on the SNS. It will start with those related to oncology. A breakthrough in precision medicine. Initiative from Aragon for a debate on health that is intended to be held at the Conference of Presidents. Although everything that represents a debate on health in the highest instances is positive, the lack of ambition of the document proposed from Aragon is truly surprising, where neither the care model nor the management model nor the personnel policy (except in what refers to the planning of professionals), nor many other very relevant things. A real disappointment the document of the Aragonese initiative. The central government supports the Spanish covid vaccine, buying 3.2 million vaccines. FENIN makes some interesting proposals, closely linked to healthcare technology, before the new legislature that is looming.

In the field of Companies, at the international level, KKR promotes the merger of IVI and General Life, to give rise to an infertility giant. At the national level, the creditors of Dentix, a former network of dental clinics, now defunct, accuse KKR of the bankruptcy of this company.

Biomedicine

Global Health

International Health Policy

National health policy

  • FENIN petitions
    • FENIN prepares some requests with 10 points for the new legislature, among them a stable regulatory environment, digital transformation of the SNS, public purchase based on value and the renewal of the health technology park (https://www.fenin.es/resources/press-notes/1011)

Companies